• ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
  • KYBORA helped identify the opportunity for Pint Pharma, established contact with BioCryst, helped build the business case and helped negotiate the final agreement for Pint Pharma.
  • Agreement further reinforces Pint Pharma’s ability to effectively file and commercialize innovative therapies in Latin America.
  • https://ir.biocryst.com/news-releases/news-release-details/biocryst-selects-pint-pharma-commercial-partner-orladeyor

About the author.


No Comments. Leave a comment  


您的电子邮箱地址不会被公开。 必填项已用 * 标注